Syntis Bio
Boston, US · Founded 2022 · Delaware corporation · 29 employees on LinkedIn · 5 known investors
Syntis Bio develops oral therapies that use the biology of the small intestine to treat conditions ranging from rare genetic disorders to common diseases. The company is advancing a pipeline of drug candidates across multiple therapeutic areas, beginning with obesity.
Also known as Syntis · Syntis Bio
Founders & leadership
Syntis Bio was founded in 2022 by Rahul Dhanda, Carlo Giovanni Traverso, and Robert Langer.
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$46.7M disclosed across 3 rounds · 2022–2025
▶$25MraisedJul 2025 · 12 investors · BiotechnologyRule 506(b)
- Chenny ZhangDirector
- Martin MadausDirector
- Carlo Giovanni TraversoDirector
- Robert LangerDirector
- Teymour Boutros-GhaliDirector
- Teymour Boutros-GhaliDirector
- Rahul DhandaExecutive Officer, Director
- Michael NannizziDirector
- Offering amount
- $26.5M
- Amount sold
- $25M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$6.3MraisedJan 2025 · 9 investors · BiotechnologyRule 506(b)
- Martin MadausDirector
- Rahul DhandaExecutive Officer, Director
- Carlo Giovanni TraversoDirector
- Teymour Boutros-GhaliDirector
- Robert LangerDirector
- Offering amount
- $9M
- Amount sold
- $6.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$15.4MraisedJan 2023 · 15 investors · BiotechnologyRule 506(b)
- MARTIN MADAUSDirector
- RAHUL K. DHANDAExecutive Officer, Director
- CARLO GIOVANNI TRAVERSODirector
- ROBERT LANGERDirector
- TEYMOUR BOUTROS-GHALIDirector
- Offering amount
- $15.4M
- Amount sold
- $15.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Syntis Bio is a Boston-based biotechnology company developing oral therapies designed to act on the biology of the small intestine. Its stated aim is to address conditions ranging from rare genetic disorders to highly prevalent metabolic diseases, with obesity and diabetes identified as initial focus areas.
The company is advancing a pipeline of drug candidates across multiple therapeutic areas, led by SYNT-101 in obesity. SYNT-101 entered a Phase 1/1b clinical trial, with the first patient dosed in March 2026 and initial single ascending dose data reported in July 2026.
Business model
Syntis Bio operates as a clinical-stage therapeutics developer, advancing proprietary oral drug candidates through clinical development.
Traction
SYNT-101, the company's lead obesity candidate, reached the clinic with the first patient dosed in a Phase 1/1b trial in March 2026, and initial single ascending dose data were reported as positive in July 2026.
Latest developments
In March 2026 the company announced the first patient dosed in the Phase 1/1b trial of SYNT-101 in obesity along with leadership additions; in June 2026 it appointed Matt Dallas as Chief Financial Officer; and in July 2026 it reported positive initial Phase 1/1b single ascending dose data for SYNT-101.
▸Full profile — market position, technology, go-to-market, geography
Market position
Syntis Bio positions itself as developing oral alternatives in obesity and diabetes treatment, an area it describes as addressing global healthcare challenges.
The company describes its differentiation as harnessing the small intestine's biology to deliver therapy orally across both rare and common conditions.
Technology
The company's approach is based on oral therapies that use the unique biology of the small intestine as the site of therapeutic action.
Go-to-market
Patients with obesity, diabetes, rare genetic disorders and other conditions in which the small intestine plays a key role.
Geography
Headquartered in Boston, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with Syntis Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 3
launches, deals, and filingsSyntis Bio reported positive initial single ascending dose results from its Phase 1/1b study of SYNT-101 in obesity.
Syntis Bio appointed Matt Dallas as Chief Financial Officer.
Syntis Bio announced the first patient dosed in a Phase 1/1b clinical trial of its obesity candidate SYNT-101, alongside key leadership additions.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Syntis Biosyntis.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Syntis Bio do?
- Syntis Bio develops oral therapies that harness small intestine biology to treat obesity, diabetes and rare diseases.
- Who founded Syntis Bio?
- Syntis Bio was founded by Rahul Dhanda, Carlo Giovanni Traverso, Robert Langer in 2022.
- Who are Syntis Bio's investors?
- Syntis Bio's investors include Bill & Melinda Gates Foundation, Bold Capital Partners, Cerity Partners Ventures, Portal Innovations, Safar Partners.
- How much funding has Syntis Bio raised?
- Syntis Bio has disclosed $46.7M raised across 3 rounds.
- Where is Syntis Bio headquartered?
- Syntis Bio is headquartered in Boston, US.